Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Searle Calan SR/Knoll Isoptin SR

Executive Summary

Searle submits preliminary data to FDA from a study completed in September on the steady-state pharmacokinetics and pharmacodynamics of sustained-release verapamil. In Oct. 3 comments on Knoll's recommendations to FDA for verapamil SR bioequivalence studies, Searle said it will soon submit final results of the study to FDA. Searle is seeking a delay in the approval of ANDA suitability petitions for the sustained-release formulation until FDA has reviewed the results of the study. Exclusivity for sustained-release verapamil runs out on Dec. 16. At least two companies have submitted ANDA suitability petitions for verapamil SR -- Lederle, in July, for a 120 mg dosage form and Pioneer Pharmaceuticals, in September, for 120 mg and 180 mg dosage strengths.

You may also be interested in...

Sandoz Pioneers Posaconazole And Silodosin In Canada

Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.

Amarin Pulls Insurer Into Hikma/Vascepa Induced Infringement Suit

US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.

Dutch Supplements Firm Caught Buying Fake Instagram Followers

Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts